L.J. Altfest & Co’s Denali Therapeutics DNLI Stock Holding History

L.J. Altfest & Co’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-4,962	Closed	-$250K	–	252
2021 Q3	$250K	Buy	4,962 +898	+22%	+$50.6K	0.05%	229
2021 Q2	$319K	Buy	4,064 +58	+1%	+$3.59K	0.07%	199
2021 Q1	$229K	Buy	+4,006	New	+$268K	0.05%	245

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

L.J. Altfest & Co's DNLI Position: Q4 2021 in Review

L.J. Altfest & Co sold out of Denali Therapeutics (DNLI) in Q4 2021, closing a stake of 4,962 shares — an estimated $250K sold.

L.J. Altfest & Co first reported a position in DNLI in Q1 2021 and held it in 3 quarters. The position peaked at $319K in Q2 2021. 213 funds tracked by Wall St. Rank hold DNLI as of Q4 2021.

L.J. Altfest & Co reported no remaining Denali Therapeutics position as of Q4 2021 after selling out during the quarter.
L.J. Altfest & Co sold 4,962 Denali Therapeutics shares in Q4 2021, an estimated $250K.
L.J. Altfest & Co first reported a position in Denali Therapeutics in Q1 2021 and held it in 3 quarters.
L.J. Altfest & Co's Denali Therapeutics position peaked at $319K in Q2 2021.
213 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2021.

Based on L.J. Altfest & Co's 13F filing for Q4 2021, filed 24 Jan 2022.